https://www.europesays.com/ch/145256/ FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) #a #and #approves #as #AtHome #disease #ENSPRYNG #Eye #FDA #first #FirstInClass #for #IL6R #inhibitor #only #Option #Roche #Roche’s #subcutaneous #TED #the #thyroid #treatment
#firstinclass — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #firstinclass, aggregated by home.social.